EMA Environmental Risk Assessment (ERA) Guideline| Freyr

 


Updated Version (Enhanced Clarity, Flow, and Professional Tone)

The European Medicines Agency (EMA) has introduced an updated Environmental Risk Assessment (ERA) Guideline, effective September 2024, reshaping how pharmaceutical companies evaluate and mitigate the environmental impact of their products.

The revised framework strengthens scientific rigor, transparency, and pharmaceutical sustainability, ensuring that every human medicinal product (HMP) undergoes a structured and comprehensive evaluation of its potential ecological risks. This update also supports the broader objectives of Europe’s Green Deal and the growing expectations for environmental accountability across the pharmaceutical sector.

Understanding Environmental Risk Assessment (ERA)

An Environmental Risk Assessment (ERA) evaluates the potential impact of a pharmaceutical active substance on the environment, including surface water, groundwater, soil, and biodiversity.

An ERA examines how an active ingredient behaves once excreted or disposed of, taking into account:

  • Physico-chemical properties (e.g., solubility, stability, degradation)
  • Ecotoxicological effects (e.g., acute and chronic toxicity to aquatic and terrestrial organisms)
  • Environmental fate (e.g., persistence, bioaccumulation, mobility)

Under the 2024 EMA ERA guideline, an ERA is required for all Marketing Authorisation Applications (MAAs) for human medicinal products—new, generic, or hybrid.

Key Highlights of the EMA Environmental Risk Assessment Guideline 2024

1. Mandatory ERA for All Human Medicinal Products

All MAAs—whether centralized, decentralized, or submitted through mutual recognition—must now include a complete ERA dossier (Module 1.6 of the eCTD).
Updated ERAs are also required for type II variations or new indications that may increase environmental exposure.

2. Two-Phase Risk Assessment Approach

The guideline maintains its established, stepwise methodology:

  • Phase I: Screening assessment to determine whether further analysis is required based on predicted environmental concentrations.
  • Phase II: A detailed evaluation, including degradation studies, environmental fate assessments, and chronic ecotoxicity testing.

Active substances exceeding the 0.01 µg/L action limit, or those with endocrine, antibacterial, or antiparasitic activity, automatically advance to Phase II.

3. Strengthened Focus on PBT/vPvB Substances

Enhanced requirements apply to substances classified as Persistent, Bioaccumulative, and Toxic (PBT) or very Persistent and very Bioaccumulative (vPvB).
Manufacturers must reduce potential environmental exposure and discuss appropriate risk-mitigation measures within the product labelling or Summary of Product Characteristics (SmPC).

4. Alignment with the 3Rs Principle

Reflecting EU animal welfare policies, the guideline emphasizes the Replacement, Reduction, and Refinement (3Rs) of animal studies.
It promotes data sharing, cross-product learning, and validated non-animal test methods wherever feasible.

5. Greater Transparency and Data Reuse

Applicants are encouraged to use existing scientific literature, public datasets, and shared regulatory information to avoid unnecessary or duplicate studies—supporting ethical testing and accelerating regulatory timelines.

Conclusion

At Freyr Solutions, our ERA specialists streamline the complex ERA regulatory landscape by delivering comprehensive scientific and regulatory support aligned with the EMA ERA Guideline 2024. Our expertise covers scientific literature review, data-gap analysis, PBT/vPvB evaluations, strategies for high-concern substances (including antibiotics and endocrine-active compounds), data waiver preparation, ERA dossier development (CTD Module 1.6), and study coordination with accredited laboratories.

Supported by certified toxicologists and regulatory experts, Freyr ensures seamless compliance for both generic and new drug MAAs across the EU. With environmental stewardship now a regulatory expectation, early alignment with the updated ERA requirements accelerates marketing authorisation, minimizes regulatory risks, and strengthens sustainability credentials.

By implementing robust ERA strategies, Freyr helps pharmaceutical companies achieve compliance while enhancing ecological responsibility and gaining competitive advantage in the EU market.

Comments

Post a Comment

Popular posts from this blog

China Cosmetic Regulations & CSAR Compliance Updates 2025

Entering China’s Booming Cosmetics Market: Why Regulatory Compliance Is Your Key to Success China’s cosmetics market is booming—and shows no signs of slowing down. As the world’s second-largest beauty market , it offers enormous potential for global brands. However, entering China takes far more than launching a high-quality product. It requires rigorous compliance with an evolving regulatory ecosystem designed to protect consumers and ensure product integrity. Understanding these regulations isn’t optional—it’s essential for successful, sustainable market entry. Key Regulatory Pillars Shaping China’s Cosmetics Landscape China’s cosmetic regulations are governed primarily by the Cosmetic Supervision and Administration Regulation (CSAR) , implemented in 2021. CSAR reshaped the regulatory environment by introducing stricter oversight and more transparent compliance expectations. CSAR Redefined Compliance Through: Cosmetic Classification: Products are divide...
Read more

AICIS Compliance: Chemical Regulations in Australia

  AICIS Compliance Overview for Chemical Manufacturers and Importers in Australia To legally introduce industrial chemicals into the Australian market, businesses must comply with the Australian Industrial Chemicals Introduction Scheme (AICIS). Below are the key steps and obligations involved: 1. Business Registration Who: Any business introducing (importing or manufacturing) industrial chemicals. When: Before introducing any chemicals. Renewal: Annually. Purpose: Enables regulators to track and enforce compliance across the industry. 2. Categorize Each Chemical Introduction Every chemical must fall into one of six categories based on risk and intended use: Category Definition Listed On the Australian Inventory of Chemical Substances (AICS); used as listed. Exempted Very low risk chemicals. Minimal paperwork. Reported Low risk; requires sim...
Read more

Canada Health Claims & Food Labeling Rules 2025

Canada’s Food and Dietary Supplement Industry Faces a Regulatory Reset A New Era of Evidence-Based Claims, Transparent Labeling, and Brand Accountability Canada’s food and dietary supplement industry is entering a pivotal era—one where health claims can no longer be used as loosely worded marketing hooks. New regulatory updates from Health Canada and the Canadian Food Inspection Agency (CFIA) are reshaping the landscape, mandating that every health-related statement be scientifically substantiated, clearly presented, and transparent to consumers . These are not minor tweaks. This is a fundamental tightening of standards —one that will redefine how products are formulated, marketed, and labeled across the board. Canadian Health Claims Under the Microscope In Canada, a health claim includes any written, visual, or symbolic statement—on packaging or in advertising—that links a food or ingredient to a health benefit. Under the Food and Drugs Act and Food and Drug Regu...
Read more